Synthaverse S.A. Stock price

Equities

SVE

PLBMDLB00018

Pharmaceuticals

Delayed Warsaw S.E. 12:55:54 2024-03-28 pm EDT 5-day change 1st Jan Change
3.91 PLN 0.00% Intraday chart for Synthaverse S.A. +2.89% -8.43%
Sales 2021 41.15M 10.35M Sales 2022 50.38M 12.67M Capitalization 391M 98.29M
Net income 2021 4M 1.01M Net income 2022 6M 1.51M EV / Sales 2021 6.73 x
Net cash position 2021 12.98M 3.26M Net cash position 2022 11.95M 3M EV / Sales 2022 7.52 x
P/E ratio 2021
66 x
P/E ratio 2022
66.6 x
Employees 234
Yield 2021 *
-
Yield 2022
-
Free-Float 57.59%
More Fundamentals * Assessed data
Dynamic Chart
Synthaverse S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Synthaverse S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Ticker to SVE from BML CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Name to SYNTHAVERSE S.A CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.(WSE:BML) dropped from S&P Global BMI Index CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
BIOMED-LUBLIN Wytw?rnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 13.398489 million in funding CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Biomed-Lublin Wytwórnia Surowic I Szczepionek S.A. Announces Earnings Results for the First Quarter of 2021 CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment Arm CI
More news
1 week+2.89%
Current month+2.36%
1 month+1.82%
3 months-8.77%
6 months-23.33%
Current year-8.43%
More quotes
1 week
3.74
Extreme 3.74
3.96
1 month
3.55
Extreme 3.552
4.11
Current year
3.55
Extreme 3.552
4.66
1 year
3.55
Extreme 3.552
6.40
3 years
2.72
Extreme 2.723
17.45
5 years
0.56
Extreme 0.56
32.80
10 years
0.39
Extreme 0.39
32.80
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Director/Board Member 69 07-12-31
Members of the board TitleAgeSince
Director/Board Member 69 07-12-31
Director/Board Member 68 08-12-31
Director/Board Member 58 07-12-31
More insiders
Date Price Change Volume
24-03-28 3.91 0.00% 53,496
24-03-27 3.91 +1.14% 40,446
24-03-26 3.866 +2.28% 51,734
24-03-25 3.78 -1.82% 56,797
24-03-22 3.85 +1.32% 70,948

Delayed Quote Warsaw S.E., March 28, 2024 at 12:55 pm EDT

More quotes
Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.
More about the company
  1. Stock
  2. Equities
  3. Stock Synthaverse S.A. - Warsaw S.E.